Doc Generici
Doc Generici, officially known as Doc Generici S.p.A., is a prominent player in the pharmaceutical industry, headquartered in Italy. Established in 2000, the company has rapidly expanded its operations across major regions in Europe, focusing on the development and distribution of generic medicines. Specialising in high-quality generics, Doc Generici offers a diverse portfolio of products that stand out for their efficacy and affordability. The company is committed to innovation and sustainability, ensuring that its offerings meet rigorous regulatory standards while addressing the needs of healthcare providers and patients alike. With a strong market position, Doc Generici has achieved notable milestones, including significant partnerships and a growing presence in the European market, solidifying its reputation as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Doc Generici's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Doc Generici's score of 27 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Doc Generici, headquartered in Italy, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Diocle S.p.A., which may influence its climate commitments and performance metrics. As of now, Doc Generici has not established any documented reduction targets or climate pledges. This lack of specific initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the absence of direct emissions data and reduction commitments, it is essential for Doc Generici to consider aligning with industry standards and frameworks, such as the Science Based Targets initiative (SBTi), to enhance its climate action efforts. This alignment could facilitate the establishment of measurable targets and improve transparency regarding its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 274,920 | 000,000 | 000,000 |
| Scope 2 | 1,310,400 | 0,000,000 | 0,000,000 |
| Scope 3 | 232,460 | 000,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Doc Generici is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
